Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.8, beating the estimate of USD -1.3567.

EBIT: As of FY2026 Q2, the actual value is USD -19.01 M.

The provided reference, a Form 8-K filing by LeonaBio, Inc., indicates that the company issued a press release on August 14, 2026, reporting its financial results for the quarter ended June 30, 2026. However, the document explicitly states that the actual financial results, operational metrics, or any forward-looking outlook or guidance were contained within the referenced Exhibit 99.1 (the press release), which is not included in the provided text. Therefore, no specific financial or operational metrics, nor any outlook or guidance, can be extracted from this document.